Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Technology appraisal guidance
Reference number: TA715
Published:
The Invitation to Participate for this appraisal will be sent out during the week commencing 31 August 2020. The final Scope and Stakeholder list will be published on the NICE website at the same time.